{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Abbreviation","name":"225Ac-J591"},{"type":"Synonym","name":"Ac 225 monoclonal antibody J591"},{"type":"Synonym","name":"Ac 225 MOAB J591"},{"type":"Synonym","name":"actinium Ac-225 anti-prostate-specific membrane antigen monoclonal antibody J591"},{"type":"Synonym","name":"actinium Ac-225 anti-PSMA monoclonal antibody J591"}],"definition":{"html":"A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.","text":"A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C153159","nciConceptName":"Actinium Ac 225 Rosopatamab Tetraxetan","termId":793676,"name":"actinium Ac 225 rosopatamab tetraxetan","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"actinium-ac-225-rosopatamab-tetraxetan"}],"links":null}